Mariangela R Resende1, Shahid Husain2, Jonathan Gubbay3, Lianne Singer4, Edward Cole4, Eberhard L Renner4, Coleman Rotstein2. 1. Division of Infectious Diseases, University of Toronto, University Health Network, Toronto, Ontario; ; Postdoctoral Scholarship National Council for Scientific and Technological Development (CNPq), University of Campinas, Sao Paulo, Brazil; 2. Division of Infectious Diseases, University of Toronto, University Health Network, Toronto, Ontario; 3. Public Health Laboratory - Toronto, Ontario Agency for Health Protection and Promotion; 4. Multi-Organ Transplant Program, University of Toronto, University Health Network, Toronto, Ontario.
Abstract
BACKGROUND: Immunocompromised individuals are more susceptible to complications produced by influenza infection. As a result, solid-organ transplant (SOT) recipients were targeted as a priority group to receive AS03-adjuvanted H1N1 influenza vaccine during 2009. OBJECTIVE: To evaluate seroconversion after one dose of adjuvanted pandemic influenza H1N1 (pH1N1) vaccine in SOT recipients. METHODS: Adult SOT recipients were enrolled to receive one 3.75 μg dose of adjuvanted pH1N1 vaccine. Serological status was tested using a hemagglutination inhibition assay before and two and four weeks postvaccination. RESULTS: The five SOT recipients (one liver, two kidney and two lung transplants) had a median age of 50 years (range 36 to 53 years), and three were male, who were a median time of three years (range two months to 15 years) post-transplant. All patients were on a double or triple immunosuppressive regimen. The prevaccination pH1N1 titre was 1:10 in four patients and 1:40 in one patient. Seroprotection was observed only in one patient, with a rise in titre from 1:40 at baseline to 1:320 at both two and four weeks after vaccination. This lung transplant recipient had documented previous infection with pH1N1. CONCLUSION: Results of the present small study call into question whether one dose of adjuvanted pH1N1 vaccine can provide seroprotection in SOT recipients.
BACKGROUND: Immunocompromised individuals are more susceptible to complications produced by influenza infection. As a result, solid-organ transplant (SOT) recipients were targeted as a priority group to receive AS03-adjuvanted H1N1 influenza vaccine during 2009. OBJECTIVE: To evaluate seroconversion after one dose of adjuvanted pandemic influenza H1N1 (pH1N1) vaccine in SOT recipients. METHODS: Adult SOT recipients were enrolled to receive one 3.75 μg dose of adjuvanted pH1N1 vaccine. Serological status was tested using a hemagglutination inhibition assay before and two and four weeks postvaccination. RESULTS: The five SOT recipients (one liver, two kidney and two lung transplants) had a median age of 50 years (range 36 to 53 years), and three were male, who were a median time of three years (range two months to 15 years) post-transplant. All patients were on a double or triple immunosuppressive regimen. The prevaccination pH1N1 titre was 1:10 in four patients and 1:40 in one patient. Seroprotection was observed only in one patient, with a rise in titre from 1:40 at baseline to 1:320 at both two and four weeks after vaccination. This lung transplant recipient had documented previous infection with pH1N1. CONCLUSION: Results of the present small study call into question whether one dose of adjuvanted pH1N1 vaccine can provide seroprotection in SOT recipients.
Authors: D Kumar; E A Blumberg; L Danziger-Isakov; C N Kotton; N B Halasa; M G Ison; R K Avery; M Green; U D Allen; K M Edwards; G Miller; M G Michaels Journal: Am J Transplant Date: 2011-10 Impact factor: 8.086
Authors: L C Willcocks; A N Chaudhry; J C Smith; S Ojha; R Doffinger; C J E Watson; K G C Smith Journal: Am J Transplant Date: 2007-06-18 Impact factor: 8.086
Authors: D Kumar; M I Morris; C N Kotton; S A Fischer; M G Michaels; U Allen; E A Blumberg; M Green; A Humar; M G Ison Journal: Am J Transplant Date: 2009-12-02 Impact factor: 8.086
Authors: Deepali Kumar; Marian G Michaels; Michele I Morris; Michael Green; Robin K Avery; Catherine Liu; Lara Danziger-Isakov; Valentina Stosor; Michele Estabrook; Soren Gantt; Kieren A Marr; Stanley Martin; Fernanda P Silveira; Raymund R Razonable; Upton D Allen; Marilyn E Levi; G Marshall Lyon; Lorraine E Bell; Shirish Huprikar; Gopi Patel; Kevin S Gregg; Kenneth Pursell; Doug Helmersen; Kathleen G Julian; Kevin Shiley; Bartholomew Bono; Vikas R Dharnidharka; Gelareh Alavi; Jayant S Kalpoe; Shmuel Shoham; Gail E Reid; Atul Humar Journal: Lancet Infect Dis Date: 2010-07-09 Impact factor: 25.071
Authors: Karl G Nicholson; Keith R Abrams; Sally Batham; Tristan W Clark; Katja Hoschler; Wei Shen Lim; Marie-Jo Medina; Jonathan S Nguyen-Van-Tam; Robert C Read; Fiona C Warren; Maria Zambon Journal: Lancet Infect Dis Date: 2010-12-16 Impact factor: 25.071
Authors: J Scharpé; P Evenepoel; B Maes; B Bammens; K Claes; A D Osterhaus; Y Vanrenterghem; W E Peetermans Journal: Am J Transplant Date: 2007-12-19 Impact factor: 8.086
Authors: Rebecca Pellett Madan; Maria Tan; Ana Fernandez-Sesma; Thomas M Moran; Sukru Emre; Andrew Campbell; Betsy C Herold Journal: Clin Infect Dis Date: 2008-03-01 Impact factor: 9.079
Authors: Aileen X Wang; Stephan Busque; Jamie Kuo; Upinder Singh; Katharina Röeltgen; Benjamin A Pinsky; Glenn M Chertow; John D Scandling; Colin R Lenihan Journal: Kidney360 Date: 2021-10-20
Authors: Sylvia D Klomp; Soufian Meziyerh; Maurits F J M Vissers; Dirk J A R Moes; Eline J Arends; Y K Onno Teng; Jesse J Swen; Aiko P J de Vries Journal: Transpl Int Date: 2022-05-16 Impact factor: 3.842